Orcosa

Orcosa is a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – RITe

Orcosa is a clinical-stage life sciences company with the Rapid Infusion Technology (RITe) drug delivery platform. The USPTO granted Orcosa a patent for cannabidiol.

Orcosa announced positive results from NYU Langone Health's multicenter Phase 1/2 clinical trial using its Rapid Infusion Technology (RITe) Platform.

Orcosa appoints Mr. Edward A. Sturchio and Mr. Robert S. Radie to Board of Directors, bolstering operational expertise to drive strategic growth.

Orcosa is a results-driven, patient-focused company that fosters a culture of authenticity and passion. Better People. Better Products. Better Outcomes

In his role as Senior Advisor, Dr. von Eschenbach provides strategic counsel on regulatory and public affairs, clinical trial development, and other critical corporate matters.

Dr. Kevin Kaplan is Orcosa Inc.'s Chief Medical Officer, directing clinical development and regulatory strategy for its drug delivery platform. He has two decades of sports-medicine experience and oversees trial designs, FDA interactions, and medical affairs.

Melissa is Orcosa's Vice President of People Strategy and has over 16 years of human resources experience. Before joining Orcosa, Melissa led human resources and talent efforts for a Fortune 200 company.

A seasoned leader in the life sciences industry with extensive operational experience. Mr Radie's career reflects a commitment to advancing patient care.

Orcosa aims to improve patient outcomes through its next-generation therapeutic delivery system, the RITe Platform.

Orcosa a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology

Orcosa is a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology - Privacy Policy